| PrEP at IAS 2017 / IAS Coverage |
 |
Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents - Dapivirine Vaginal Ring Safe and Acceptable in US Adolescents - (08/07/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
An Open Label Multiple Dose Phase 1 Assessment of Long Acting Rilpivirine - Long-Acting Rilpivirine Suppresses Replication in Rectal Explants - Mark (08/07/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
One-year experience with Pre-Exposure Prophylaxis (PrEP) Implementation in France with TDF/FTC - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Is on-demand PrEP with TDF/FTC effective among MSM with infrequent sexual intercourse? - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Potential for HIV transmission among adolescents and young adults receiving antiretroviral therapy - 'PrEP missed opportunities' - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Impact of microbiota on female genital tissue and plasma concentrations of dapivirine - (08/02/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Limited implementation of HIV pre-exposure prophylaxis among public health departments in North Carolina, United States - (08/02/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (08/02/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Reasons for not using PrEP in a national on-line sample of U.S. men who have sex with men (MSM) - Cost, Side Effects, Access Lead Reasons for PrEP Nonuse by US MSM - (07/31/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Experiences and perceptions of PrEP among gay, MSM, and TGW in the PROUD study in England: 'Rules' of Sex, Psychological, Psychosocial Benefits - (07/31/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Adherence intentions, long-term adherence and HIV acquisition among PrEP users in the PROUD open-label randomised control trial of PrEP in England - (07/31/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Long term follow up of PROUD Evidence for high continued HIV exposure and durable effectiveness of PrEP - (07/31/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Is on-demand PrEP a suitable tool for MSM who practice chemsex? Results from a sub-study of the ANRS-IPERGAY trial - Chemsex Users in IPERGAY Twice as Likely to Use As-Needed PrEP - (07/28/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus - (07/27/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial - (07/27/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days - (07/26/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 |
|
A Single Monotherapy Dose of MK-8591,a Novel NRTI, Suppresses HIV for Ten Days - (02/24/16)
Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA |
|
Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis - (02/24/16)
Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA |
| |
|
|
| News Updates |
|
Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from ...
Yahoo Finance | May 13, 2019
|
|
NIH awards will advance development of vaccines for sexually transmitted infections
NIH | May 5, 2019
|
|
Cancer. 2019 May 3. doi: 10.1002/cncr.32158
|
|
Boston hospital receives largest philanthropic gift in history for HIV/AIDS vaccine research
WCVB Boston | April 25, 2019
|
|
Novel antibody may suppress HIV for up to four months
NIH | April 17, 2019
|
|
Scientists find another way HIV can hide from vaccines
Yale News | April 10, 2019
|
|
PR Newswire | March 28, 2019
|
|
Aaron Diamond AIDS Research Center to Join Columbia University
Columbia University | March 20, 2019
|
|
Curing HIV just got more complicated. Can CRISPR help?
Science Magazine | March 15, 2019
|
|
Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach
PLoS Med. 2019 Mar 4;16(3):e1002756. doi: 10.1371/journal.pmed.1002756. eCollection 2019 Mar.
|
|
This is Not A Cure for My H.I.V.
New York Times | March 9, 2019
|
|
One step closer to ultra-long-acting PREP?
AIDS: march 2019
|
|
NATAP | February 20th, 2019
|
|
Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate |
|
Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4
|
|
NIH Clinical Trial to Track Outcomes of Liver Transplantation from HIV-Positive Donors to HIV-Positive Recipients
HIV.gov | February 15, 2019
|
|
Ending the HIV Epidemic: A Plan for the United States
NIH | February 7, 2019
|
|
Study of PrEP and vaginal ring for HIV prevention begins in girls and young women
NIH | February 7, 2019
|
|
HIV-AIDS drug could help treat Alzheimer's and other age-related diseases, Brown researchers say
The Providence Journal | February 6, 2019
|
|
Hodgkin's lymphoma and its association with EBV and HIV infection
Crit Rev Clin Lab Sci. 2018 Mar;55(2):102-114. doi: 10.1080/10408363.2017.1422692. Epub 2018 Jan 9
|
|
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer
A Systematic Review
|
|
Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation
BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.
|
|
PLoS One. 2019 Jan 16;14(1):e0210398. doi: 10.1371/journal.pone.0210398. eCollection 2019
|
|
Incidence and Correlates of STIs among Black Men who have Sex with Men Participating in the HPTN 073 PrEP Study.
Clin Infect Dis. 2019 Jan 7. doi: 10.1093/cid/ciy1141.
|
|
Scientists achieve the first proof of concept for an HIV broadly-neutralising antibody vaccine in ...
aidsmap | January 2, 2019
|
|
Potential of HIV-Protective Drugs Administered Via Rectal Douches
Infectious Disease Advisor | December 26, 2018
|
|
AIDS -- an approach for targeting HIV reservoirs
Eurek Alert | December 20, 2018
|
|
AIDS: An approach for targeting HIV reservoirs
Science Daily | December 20, 2018
|
|
Study Determines Why Patients With HIV Have Higher Rates of Cancer
AJMC.com Managed Markets Network | December 14, 2018
|
|
NIH to fund HIV care and prevention research in the South
Healio | December 14, 2018
|
|
Removable PrEP implant produces high drug levels in rabbits; further studies planned
aidsmap | November 15, 2018
|
|
Johns Hopkins researchers examine testosterone use to increase BMD in HIV-infected men
EurekAlert | December 12, 2018
|
|
A protein complex from human milk enhances the activity of antibiotics and drugs against Mycobacterium tuberculosis
Antimicrob Agents Chemother. 2018 Nov 12. pii: AAC.01846-18. doi: 10.1128/AAC.01846-18
|
|
With HIV/AIDS Research Threatened, NIH Looks For Stem-Cell Alternatives
Rolling Stone | December 11, 2018
|
|
Uganda starts tests for long acting injectable ARVs
New Vision | November 9, 2018
|
|
Dapivirine and Contraceptive Levels in Dual-Purpose Vaginal Ring: 14-Day Study
HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid
|
|
Tenofovir Rectal Douche Provides Protective Drug Levels in MSM Colon Tissue - on-demand, behaviorally-congruent
HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid
|
|
Subcutaneous TAF Implants Pass 63-Day Test in Rabbits for Long-Acting PrEP
HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid
|
|
High MSM Interest in Long-Acting PrEP Regardless of Current Oral PrEP Use
HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid
|
|
The Miami monkey cured with two antibodies
aidsmap | Oct 26, 2018
|
|
The long tail of injectable PrEP is especially long for women
aidsmap | Oct 25, 2018
|
|
